Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study

[1]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[2]  W. Litchy,et al.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy , 2017, BMC Neurology.

[3]  Sanjiv J. Shah,et al.  Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). , 2017, Circulation. Heart failure.

[4]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[5]  P. Hawkins,et al.  Systemic amyloidosis , 2016, The Lancet.

[6]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[7]  S. Frusconi,et al.  The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience , 2016, Journal of cardiovascular medicine.

[8]  H. Katus,et al.  Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study , 2015, Drug design, development and therapy.

[9]  B. Bettencourt,et al.  Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study , 2015, Orphanet Journal of Rare Diseases.

[10]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[11]  H. Katus,et al.  Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study , 2015, Clinical Research in Cardiology.

[12]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[13]  E. Nordh,et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.

[14]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[15]  M. Saraiva,et al.  Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[16]  M. Gobbi,et al.  Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[17]  E. Wanker,et al.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report , 2012, Clinical Research in Cardiology.

[18]  M. Saraiva,et al.  Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: “In Vivo” Evidence from FAP Mice Models , 2012, PloS one.

[19]  L. Padeletti,et al.  Cardiac amyloidosis: the heart of the matter , 2013, Internal and Emergency Medicine.

[20]  F. Perfetto,et al.  Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? , 2011, Journal of cardiovascular medicine.

[21]  H. Katus,et al.  Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis , 2010, Clinical Research in Cardiology.

[22]  S. Sang,et al.  Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[23]  M. Saraiva,et al.  Binding of epigallocatechin‐3‐gallate to transthyretin modulates its amyloidogenicity , 2009, FEBS letters.

[24]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[25]  W. Hunstein.  Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? , 2007, Blood.

[26]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.